A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Clinical trial NCT05041062 · COMPLETED
Trial details
- NCT number
- NCT05041062
- Sponsor
- University of Chicago
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-01
- Primary completion
- 2023-04-13
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.